Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KP.2 mRNA COVID-19 vaccine
- Development stage
- Approved
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
The KP.2 mRNA COVID-19 vaccine refers to the updated, monovalent 2024–2025 formulation of messenger RNA (mRNA) vaccines designed to target the SARS-CoV-2 Omicron KP.2 subvariant (a descendant of the JN.1 lineage). Developed independently by Pfizer-BioNTech (as Comirnaty) and Moderna (as Spikevax), these vaccines utilize lipid nanoparticle-encapsulated mRNA encoding the prefusion-stabilized spike protein of the KP.2 variant. Upon administration, host cells translate the mRNA to express the KP.2 spike antigen, which stimulates a robust humoral and cellular immune response, including the production of neutralizing antibodies and T-cell activation. The vaccine is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 6 months and older, providing updated protection against circulating JN.1-lineage subvariants.
- Brand names
- ComirnatySpikevax
- Other names
- KP.2 monovalent mRNA COVID-19 vaccineKP.2 monovalent mRNA vaccineKP.2 mRNA vaccineKP.2 spike mRNA vaccineOmicron KP.2-adapted mRNA COVID-19 vaccineOmicron KP.2-adapted mRNA vaccinemonovalent KP.2 mRNA vaccine
02
Targets
ACE2 (Angiotensin-converting enzyme 2)SARS-CoV-2 spike
Beyond the preview
Go deeper on KP.2 mRNA COVID-19 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KP.2 mRNA COVID-19 vaccine.